A formal European Commission approval has now arrived for Sandoz and Polpharma Biologics’ partnered Tyruko (natalizumab) biosimilar to Tysabri, the “first and only biosimilar for relapsing forms of multiple sclerosis in Europe,” opening the door for Sandoz to begin marketing the product imminently.
Under a 2019 agreement, the Polpharma Biologics-developed biosimilar can be commercialized by Sandoz in all global markets